| The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity J Canon, K Rex, AY Saiki, C Mohr, K Cooke, D Bagal, K Gaida, T Holt, ... Nature 575 (7781), 217-223, 2019 | 1758 | 2019 |
| Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a … AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ... Jama 317 (23), 2392-2401, 2017 | 837 | 2017 |
| Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164 DT Le, TW Kim, E Van Cutsem, R Geva, D Jäger, H Hara, M Burge, ... Journal of clinical oncology 38 (1), 11-19, 2020 | 830 | 2020 |
| Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in … HA Burris III, HI Hurwitz, EC Dees, A Dowlati, KL Blackwell, B O'Neil, ... Journal of clinical oncology 23 (23), 5305-5313, 2005 | 811 | 2005 |
| T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 … PA Ott, YJ Bang, SA Piha-Paul, ARA Razak, J Bennouna, JC Soria, ... Journal of Clinical Oncology 37 (4), 318-327, 2019 | 769 | 2019 |
| CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts … AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, MR Mahoney, BH O'Neil, ... Journal of Clinical Oncology 32 (15_suppl), LBA3-LBA3, 2014 | 622 | 2014 |
| The proteasome as a target for cancer therapy PM Voorhees, EC Dees, B O’Neil, RZ Orlowski Clinical cancer research 9 (17), 6316-6325, 2003 | 590 | 2003 |
| Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB … AP Venook, D Niedzwiecki, F Innocenti, B Fruth, C Greene, BH O'Neil, ... Journal of Clinical Oncology 34 (15_suppl), 3504-3504, 2016 | 492 | 2016 |
| Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies NL Spector, W Xia, H Burris III, H Hurwitz, EC Dees, A Dowlati, B O'Neil, ... Journal of clinical oncology 23 (11), 2502-2512, 2005 | 481 | 2005 |
| Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1–positive cervical cancer: results from the phase Ib KEYNOTE-028 trial JS Frenel, C Le Tourneau, B O’Neil, PA Ott, SA Piha-Paul, C Gomez-Roca, ... Journal of Clinical Oncology 35 (36), 4035-4041, 2017 | 455 | 2017 |
| Hepatocellular carcinoma: consensus recommendations of the national cancer institute clinical trials planning meeting MB Thomas, D Jaffe, MM Choti, J Belghiti, S Curley, Y Fong, G Gores, ... Journal of clinical oncology 28 (25), 3994-4005, 2010 | 438 | 2010 |
| High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history BH O'Neil, R Allen, DR Spigel, TE Stinchcombe, DT Moore, JD Berlin, ... Journal of Clinical Oncology 25 (24), 3644-3648, 2007 | 367 | 2007 |
| Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers T Bekaii-Saab, MA Phelps, X Li, M Saji, L Goff, JSW Kauh, BH O'Neil, ... Journal of clinical oncology 29 (17), 2357-2363, 2011 | 355 | 2011 |
| Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma BH O’Neil, JM Wallmark, D Lorente, E Elez, J Raimbourg, C Gomez-Roca, ... PloS one 12 (12), e0189848, 2017 | 262 | 2017 |
| Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma BH O'Neil, LW Goff, JSW Kauh, JR Strosberg, TS Bekaii-Saab, R Lee, ... Journal of Clinical Oncology 29 (17), 2350-2356, 2011 | 177 | 2011 |
| Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid … M Fakih, B O'Neil, TJ Price, GS Falchook, J Desai, J Kuo, R Govindan, ... Journal of Clinical Oncology 37 (15_suppl), 3003-3003, 2019 | 176 | 2019 |
| Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase II KEYNOTE-158 study J Strosberg, N Mizuno, T Doi, E Grande, JP Delord, R Shapira-Frommer, ... Clinical cancer research 26 (9), 2124-2130, 2020 | 175 | 2020 |
| A multidisciplinary approach to pancreas cancer in 2016: a review EL Fogel, S Shahda, K Sandrasegaran, J DeWitt, JJ Easler, DM Agarwal, ... Official journal of the American College of Gastroenterology| ACG 112 (4 …, 2017 | 141 | 2017 |
| A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas T Bekaii-Saab, J Markowitz, N Prescott, W Sadee, N Heerema, L Wei, ... Clinical Cancer Research 15 (18), 5895-5901, 2009 | 141 | 2009 |
| First-in-human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory solid tumors SA Piha-Paul, JC Sachdev, M Barve, P LoRusso, R Szmulewitz, SP Patel, ... Clinical Cancer Research 25 (21), 6309-6319, 2019 | 132 | 2019 |
